• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Medications in type-2 diabetics and their association with liver fibrosis

    2020-07-10 07:08:02MohamedTausifSiddiquiHinaAminRajatGargPravallikaChadalavadaWaelAlYamanRocioLopezAmandeepSingh
    World Journal of Gastroenterology 2020年23期

    Mohamed Tausif Siddiqui, Hina Amin, Rajat Garg, Pravallika Chadalavada, Wael Al-Yaman, Rocio Lopez,Amandeep Singh

    Abstract

    Key words: Diabetes medications; Anti-lipid medications; Antihypertensive medication;Fatty liver; Advanced fibrosis

    INTRODUCTION

    Non-alcoholic fatty liver disease (NAFLD) has been emerging as one of the most important cause of liver disease worldwide, and it is likely to become a leading cause of end-stage liver disease (ESLD) in the near future[1]. The global prevalence of NAFLD has been estimated to be around 25%, affecting nearly 1.8 billion individuals worldwide[2,3], of which 51.6 million are in the United States alone, representing 21.9%of adult United States population[4]. The pathological spectrum of NAFLD can range from benign hepatic steatosis to more severe forms such as non-alcoholic steatohepatitis (NASH), advanced fibrosis (AF), cirrhosis, and ESLD[5]. The subtype of NAFLD characterized by NASH is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death, and result in significant health-care and economic burden[6].

    As the epidemics of obesity and type 2 diabetes mellitus (T2D) increase worldwide,the prevalence of NAFLD is rising rapidly[6]. Recently T2D has been recognized as a major risk factor for progressive liver disease, with standardized mortality rates for cirrhosis greater than that for cardiovascular disease[7]. A study by Williamsonet al[8]showed that 56.9% patients with T2D had steatosis on ultrasonography. After excluding patients with secondary cause of steatosis, prevalence of NAFLD was 42.6%in their population[8]. Independent predictors for NAFLD in their patient population were body mass index (BMI), duration of diabetes, Hemoglobin A1c, triglyceride levels, and metformin use[8]. A meta-analysis of 17 studies involving 10897 patients concluded that the overall prevalence of NAFLD among patients with T2D is significantly higher and optimal management of T2D may play a role in preventing NAFLD[9]. Patients with T2D are usually on a number of prescription medications.These include oral hypoglycemics, insulin, anti-lipid and anti-hypertensive medications. It is known that diabetes mellitus is a risk factor for AF in NAFLD,however, not all NAFLD patients with diabetes develop AF. This may be due to effects of certain medications used to treat diabetes and dyslipidemia[10]. In one study the use of angiotensin converting enzyme (ACE) inhibitor was observed to reduce the risk of AF in chronic Hepatitis C patients[11]. There is paucity of data on the association of various medications with AF in patients with T2D, which is a well-known risk factor for advanced liver disease. The aim of this study was to assess the association of commonly used medications (anti-lipid, anti-diabetic and anti-hypertensive medications) with AF in patients with T2D and NAFLD.

    MATERIALS AND METHODS

    Study design

    This is a retrospective cohort study.

    Data source and patient selection criteria

    Our study protocol was approved by Institutional Review Board of the Cleveland Clinic. We used the International Classification of Disease 9thRevision Clinical Modification (ICD-9 CM) coding system and identified the patients with T2D (ICD 9 code: 250.xx) and suspected NAFLD (ICD 9 code: 571.8 and 571.9) from the Cleveland Clinic Electronic Medical Record System. We included patients who were 18 years or older and who underwent liver biopsy between January 1, 2000 to December 31, 2015.The decision to do liver biopsy was based on the clinical judgment of treating physician. Biopsies were reviewed by a group of expert gastroenterology and hepatology pathologists to detect fibrosis. Liver biopsies were classified according to NASH-CRN classification. Fibrosis was staged on a 5-point scale: Stage 0 = no fibrosis,stage 1 = zone 3 perisinusoidal/perivenular fibrosis, stage 2 = zone 3 and periportal fibrosis, stage 3 = septal/bridging fibrosis, and stage 4 = cirrhosis. AF was defined as fibrosis stage 3-4. We excluded the patients who did not have liver biopsy within 24 mo of T2D diagnosis, as well as, those with incomplete medical records or with secondary causes of hepatic steatosis {viral hepatitis, hemochromatosis, α1-antitrypsin deficiency, Wilson disease, lipodystrophy, starvation, on parenteral nutrition,abetalipoproteinemia, and using certain medications (corticosteroids, valproate, and antivirals)} were excluded. Patients were also excluded if they consumed more than 30 g of alcohol per day for males or more than 20 g per day for females. We collected age, gender, patient demographics including race, BMI, systolic and diastolic blood pressure, existing concurrent comorbidities such as hypertension, hyperlipidemia,laboratory results, medications and their duration of use.

    Statistical analysis

    We used Pearson’s chi-square (χ2) tests or Fisher’s Exact to analyze the differences in patient demographics. For continuous variables, we performed a one-way Analysis of Variance (ANOVA) or the non-parametric Kriskal Wallis tests. Findings are reported either as mean ± SD, median (25th, 75thpercentiles) or percentage. A multinomial logistic regression analysis was performed to identify the independent clinical factors associated AF. Age, gender, race, BMI, concurrent hypertension, hyperlipidemia,chronic kidney disease, inflammatory bowel disease, deep vein thrombosis, use of oral hypoglycemic medications, insulin, antihypertensive medications, antilipidemic medications, and aspirin were considered for inclusion in the logistic regression model and a stepwise variable selection method was used to choose the final model;variables withP< 0.10 were included in the final model. We adjusted for age, gender,race and BMI. SAS (Version 9.4, The SAS Institute, Cary, NC, United States) was used for all analyses and a two-sidedPvalue of less than 0.05 was considered to be statistically significant.

    RESULTS

    After applying inclusion and exclusion criteria, a total of 1183 subjects were identified and included in the final analysis. Out of these patients, 32.2% (n= 381) had AF(fibrosis score 3-4) on their liver biopsy. The demographics and clinical characteristics of participants are shown in Table 1. The mean age at liver biopsy for our cohort was 52 ± 11 years and 65.7% patients were female. The majority of patients were Caucasians (85.1%) followed by African American (9.2%) and other races (5.7%).Overall mean systolic and diastolic blood pressures (SBP and DBP) in our cohort were 129.6 ± 17.1 mmHg and 73.7 ± 11.0 mmHg, respectively. There was no difference in the SBP between the two fibrosis groups (129.5 ± 16.6vs129.9 ± 18.2,P= 0.66) but significant difference existed between the DBP in the two groups (74.5 ± 10.5vs72.1 ±11.7,P< 0.001). Hypertension and hyperlipidemia were more prevalent in Fibrosis 0-2 group (70%vs57.7%,P< 0.001; 68.2%vs49.1%,P< 0.001) whereas CKD was more prevalent in Fibrosis 3-4 group (4.6%vs13.6%,P< 0.001).

    In terms of medications in the AF group (n= 381), 51.7% were on oral hypoglycemic, 30.1% were on insulin, 65.4% were on antihypertensive and 37.3% on anti-lipidemic medications for a median duration of 17.4 mo, 8.3 mo, 18.1 mo, and 20.9 mo respectively. Table 2 presents a summary of medication use in our cohort. Figure 1 shows a visual representation of medication usage among the two groups.Unadjusted and adjusted odds ratio (OR) of clinical factors associated with AF have been listed in the Table 3. Amongst oral hypoglycemic medications, Metformin use was associated with decreased risk of AF [OR = 0.64 (0.49, 0.82),P< 0.001]. We did not find a statistically significant association between Glipizide (P= 0.75),Pioglitazone (P= 0.11) or Sitagliptin/Januvia (P= 0.79) and the presence of AF.Liraglutide use was also associated with decreased risk of AF [OR = 0.30 (0.14, 0.64),P= 0.002]. We did not find a statistically significant association between the use of Detemir/Levemir (P= 0.83), Lantus (P= 0.14), Humulin (P= 0.35) or Byetta (P= 0.65)and the presence of AF. Amongst anti-hypertensive medications, use of Lisinopril [OR= 0.74 (0.56, 0.97),P= 0.031] and Hydrochlorothiazide [OR = 0.57 (0.43, 0.76),P<0.001] were associated with decreased risk of AF. In contrast, use of Furosemide [OR =1.9 (1.4, 2.5),P< 0.001) and Spironolactone [OR = 3.1 (2.0, 4.6),P< 0.001] were associated with increased risk of AF. For other anti-hypertensive medications we did not find any statistically significant association. Amongst anti-lipidemics, use of Atorvastatin [OR = 0.62 (0.44, 0.86),P= 0.004] and Simvastatin [OR = 0.61 (0.44, 0.85),P= 0.003] were associated with decreased risk of AF. We did not find a statistically significant association for other anti-lipid agents.

    DISCUSSION

    This study is the first study in the literature exploring the association of different pharmacological modalities used in the treatment of T2D and AF in biopsy-proven NAFLD. Our study highlights the critical findings that certain prescription medications taken by patients with T2D are associated with decreased risk of AF.These medications might be playing a protective role by decreasing the rate of NAFLD progression. In our cohort of patients, oral hypoglycemic like metformin and liraglutide, anti-hypertensive medications like Lisinopril and Hydrochlorothiazide,and anti-lipid medication like Atorvastatin and Simvastatin are associated with decreased risk of AF, suggesting that they could perhaps have a protective effect on NAFLD.

    Diabetes is a known cause of NAFLD and advanced liver disease is the most common cause of deaths in patients with T2D, showing a reciprocal relationship between the two. Treatment approaches in T2D mainly include either decreasing insulin resistance (metformin, thiazolidinediones) or increasing circulating insulin levels (exogenous insulin or sulfonylureas)[10,12,13]. A study by Hazlehurstet al[14].explored the role of different classes of antidiabetic medications as a therapeutic disease modifying effect on NAFLD in patients with T2D. They specifically highlighted a promising role of metformin and GLP-1 agonists in treatment of NAFLD[14]. Our observation that Metformin is associated with a decrease in AF might suggests that insulin resistance is likely implicated in the pathophysiology of development of hepatic fibrosis. Metformin is effective as an anti-diabetic drug due to its ability to improve peripheral insulin sensitivity. Lowering blood glucose is achieved by decreasing gluconeogenesis in the liver, stimulating glucose uptake in the muscle, and increasing fatty acid oxidation in adipose tissue[15]. At the molecular level,some of the beneficial effects of metformin have been associated to the phosphorylation and nuclear export of Liver-kinase B1 which activates adenosine monophosphate-activated protein kinase, a regulator of energy metabolism, able to stimulate ATP-producing catabolic pathways (glycolysis, fatty acid oxidation, and mitochondrial biogenesis) and to inhibit ATP-consuming anabolic processes(gluconeogenesis, glycogen, fatty acid, and protein synthesis), leading to decreased glucose levels in the blood and ultimately decreased glucose mediated organ injury[16].A meta-analysis showed a 50% reduction in Hepatocellular carcinoma (HCC)incidence with metformin use (n= 8 studies; OR = 0.50, 95%CI: 0.34-0.73), further strengthening our observation that Metformin likely plays a protective role in liver disease[17]. In addition to Metformin, Liraglutide also showed a decreased risk of AF.Liraglutide is a glucagon-like-peptide 1 (GLP-1) analog that binds to the same receptors as the endogenous metabolic hormone GLP-1 and improves glucosehomeostasisviaits glucose-dependent stimulation of insulin secretion, inhibition of postprandial glucagon secretion and delayed gastric emptying[18]. A recent multicenter, double-blind, randomized, placebo-controlled phase 2 study published by Armstronget al[19]showed that 39% of the patients who received liraglutide and underwent end-of-treatment liver biopsy had resolution of definite NASH compared with 9% of the patients in the placebo group [relative risk 4.3 (95%CI: 1.0-17.7),P=0.01]. Also they noted that 9% of the patients in the liraglutide group had progression of fibrosis compared to 36% in the placebo group [0.2 (0.1-1.0),P= 0.04], further supporting the findings of our study.

    Table 1 Demographic and clinical characteristics

    Figure 1 Graphical presentation of differences in medication usage among patients in different fibrosis groups.

    Another observation made in our study was the protective role of Lisinopril, an angiotensin-converting enzyme, a medication commonly prescribed to lower blood pressure, in patients with T2D. A recent meta-analysis showed that renin angiotensin system inhibitors resulted in a marginally significant reduction in liver fibrosis score[MD = -0.30, 95%CI (-0.62, 0.02),P= 0.05] and a significant reduction in liver fibrosis area [MD = -2.36%, 95%CI (-4.22%, -0.50%),P= 0.01], hence concluding that these medications perhaps play a more protective role in liver disease[20]. Multiple animal studies have suggested that angiotensin II contributes to hepatic fibrosis by interacting with the angiotensin II receptor type 1 (AT1 receptor) leading to the activation of hepatic stellate cells-the main collagen producing cells in the liver[21-23].One animal model illustrated that inhibition of angiotensin II decreases the generation of reactive oxygen species, resulting in less collagen synthesis by hepatic stellate cells,and downregulates the vascular endothelial growth factor[24]. While another model suggested that angiotensin-receptor blockade leads to downregulation pro inflammatory/profibrotic cytokines[25], thus attenuating liver fibrosis. A study investigating the effect of Ramipril, an ACE inhibitor on the incidence of diabetes suggested that the use of ACE inhibitors may reduce the incidence of hyperglycemia in new diabetics as well as in those with insulin resistance[26]. Hence, this additional benefit that ACE inhibitors provide in diabetics may also contribute in part to the observed reduction in fibrosis in patients with NAFLD.

    Our data in a large cohort of well characterized patients with NAFLD also suggests that the use of statins like Atorvastatin and Simvastatin is associated with reduced risk of advanced hepatic fibrosis in NAFLD patients with T2D. In the presence of NAFLD and hyperinsulinemia, there is accumulation of lipid molecules in the liver which further leads to inflammation and lipotoxicity[27], playing a fundamental role in the pathogenesis of hepatic steatosis, steatohepatitis and fibrosis. Statins, the mainstay of lipid-lowering therapy, improves liver outcomes by lowering lipids and lipotoxicity[28]. Apart from that, statins have also been reported to reduce cardiovascular risks and mortality in patients with NAFLD[29]. In a Swedish study that explored changes in liver histology over time among patients with NAFLD, there was less fibrosis in patients prescribed a statin[30]. However, previous studies have concluded that statin should not be used for NASH alone without the association of dyslipidemia[31]. For the simplification of the medication classification furosemide and spironolactone were considered under antihypertensive group, while these medications do lower blood pressure, they are often used primarily as diuretics. It is possible that patients were receiving these medications for advanced liver disease associated fluid overload or ascites.

    The prevalence of NAFLD has progressively increased over the past 10 years,making it a significant health burden and the treatment of NAFLD is of prime concern to health care professionals and patients due to significant mortality and morbidity it implies[32]. Treatment is focused on lifestyle changes and managing the associated comorbidities. Lifestyle modification includes attention to patient’s diet by promoting intake of fruits and vegetables and avoiding high fat content; and increasing physical activity[33,34]. Obesity treating drugs like Orlistat and bariatric surgery may also help in selected cases in achieving weight loss that can help in NAFLD[34,35]. Other measures include insulin sensitizers, drugs that reduce blood lipids, glucagon-mimetics, drugs that may reduce fibrosis, angiotensin receptor blockers, and medicines believed to reduce endoplasmic reticular stress such as vitamin E, ursodeoxycholic acid, and Sadenosyl methionine[30]. Several newer agents such as Obeticholic acid and GFT505 have shown promising results and various other pharmacotherapies are still being studied[32]. Treatment options such as gene based therapeutic treatment of NAFLD in diabetics are still in the experimental phases, however they could offer promising therapeutic options in the near future[36].

    Our study has several limitations. It is a retrospective analysis and association does not imply causal relationship. In our multivariable analysis we adjusted for possible confounders, however, it is possible that one or more unknown confounders might be responsible for some of the results which we have observed. Since our studypopulation was recruited from a single center, generalization should be avoided. In addition, despite using the strict exclusion criteria, some degree of recall bias may have been present while evaluating for alcohol consumption and medication use. On the other hand, the large sample size of biopsy proven NAFLD patients is a major strength of the current study.

    Table 2 Medication use

    1Kruskal-Wallis test.2Pearson's χ2 test. Statistics presented as median (P25, P75) or n (%).

    In conclusion, in this large cohort of T2D with biopsy proven NAFLD, patients who were receiving Metformin, Liraglutide, Lisinopril, Hydrochlorothiazide, Atorvastatin and Simvastatin were less likely to have AF on liver biopsy while patients who were receiving Furosemide and Spironolactone had a higher likelihood of having AF on liver biopsies. Although our study does not indicate a causation it is important that physicians are aware of this key association. In the management and treatment of patients with NAFLD, clinicians should consider both liver disease and the associated metabolic co-morbidities. Along with diet and physical activity, focus should be given on specific pharmacological therapies that have been proven to be beneficial in NAFLD. Despite the consistent increase in the knowledge of therapeutic options for NAFLD, its management still remains a challenge for the scientific community and additional clinical trials are needed to evaluate the efficacy of various agents in NAFLD and T2D.

    Table 3 Assessment of associations between clinical factors and advanced fibrosis

    ARTICLE HIGHLIGHTS

    Research objectives

    We aimed to understand the association of the different pharmacologic modalities used in the treatment of diabetes mellitus on the progression of liver fibrosis in NAFLD patients with type-2 diabetes.

    Research methods

    We identified all adult patients with type-2 diabetes mellitus who underwent liver biopsy for suspected NAFLD at the Cleveland Clinic between January 1, 2000 to December 31, 2015. We retrospectively reviewed a cohort of 1183 patients with type-2 diabetes and biopsy proven NAFLD. We compared demographics, clinical characteristics, and differences in pattern of medication use in patients who had biopsy-proven NAFLD with and without advance fibrosis.A univariate and multivariate analysis was performed to assess the association of different classes of medication with and without the presence of AF.

    Research results

    We found that the patients who were receiving Metformin, Liraglutide, Lisinopril,Hydrochlorothiazide, Atorvastatin and Simvastatin were less likely to have AF on biopsy, while patients who were receiving furosemide and spironolactone were more likely to have AF when they underwent liver biopsy. Diabetic patients with chronic kidney disease were more likely to have AF on liver biopsy.

    Research conclusions

    Our study highlights the protective role of some of the commonly used medications in the treatment of type-2 diabetes mellitus. We propose that Metformin, Liraglutide, Lisinopril,Hydrochlorothiazide, Atorvastatin and Simvastatin may have a beneficial role in slowing down the progression of NAFLD.

    Research perspectives

    Although it is possible that some unknown confounding factors could have impacted our findings, this study lays a solid groundwork for future prospective studies to further investigate the protective role of these medications on the progression of liver fibrosis in diabetic patients with NAFLD.

    久久久久久久久中文| 高潮久久久久久久久久久不卡| 亚洲欧美日韩高清专用| 精品国产乱码久久久久久男人| 欧美最黄视频在线播放免费| 国产亚洲av嫩草精品影院| 叶爱在线成人免费视频播放| 中文字幕人妻丝袜一区二区| 18禁黄网站禁片免费观看直播| 亚洲成人久久性| 国语自产精品视频在线第100页| 99精品在免费线老司机午夜| 熟女少妇亚洲综合色aaa.| 精品无人区乱码1区二区| 91久久精品国产一区二区成人 | 人妻久久中文字幕网| 欧美日韩福利视频一区二区| 亚洲国产欧美一区二区综合| 舔av片在线| 老汉色av国产亚洲站长工具| 婷婷六月久久综合丁香| 国产一区二区在线观看日韩 | 成人18禁在线播放| av片东京热男人的天堂| 成人性生交大片免费视频hd| 高清毛片免费观看视频网站| 夜夜爽天天搞| 国产黄色小视频在线观看| 亚洲精品美女久久久久99蜜臀| 精品国产美女av久久久久小说| 一级a爱片免费观看的视频| 好男人电影高清在线观看| 18禁观看日本| 久久久久久人人人人人| 亚洲专区国产一区二区| 日韩精品中文字幕看吧| 欧美乱色亚洲激情| 一级毛片女人18水好多| 成人18禁在线播放| 法律面前人人平等表现在哪些方面| 国产成人欧美在线观看| 99久国产av精品| 无人区码免费观看不卡| 1024手机看黄色片| 欧美乱妇无乱码| 两性夫妻黄色片| 久久久久九九精品影院| 桃红色精品国产亚洲av| 午夜福利在线观看吧| 老鸭窝网址在线观看| 69av精品久久久久久| 欧美日韩乱码在线| 日日干狠狠操夜夜爽| 亚洲av日韩精品久久久久久密| 国产私拍福利视频在线观看| 99久久精品热视频| 国产伦精品一区二区三区视频9 | 欧美一级a爱片免费观看看| 真实男女啪啪啪动态图| 一本精品99久久精品77| 久久久久性生活片| 中文字幕精品亚洲无线码一区| 国模一区二区三区四区视频 | 白带黄色成豆腐渣| 色综合婷婷激情| 99国产精品99久久久久| 窝窝影院91人妻| 国产av一区在线观看免费| 99精品在免费线老司机午夜| 精品久久久久久久久久免费视频| 亚洲欧洲精品一区二区精品久久久| 精品午夜福利视频在线观看一区| 色视频www国产| 色视频www国产| 婷婷丁香在线五月| e午夜精品久久久久久久| bbb黄色大片| bbb黄色大片| 亚洲人成伊人成综合网2020| 成人性生交大片免费视频hd| 久久午夜亚洲精品久久| 免费看十八禁软件| or卡值多少钱| 亚洲熟妇中文字幕五十中出| 老熟妇仑乱视频hdxx| 亚洲精品在线美女| 亚洲电影在线观看av| 精品国产亚洲在线| 亚洲欧美精品综合一区二区三区| 成人高潮视频无遮挡免费网站| 两性午夜刺激爽爽歪歪视频在线观看| 久久久久免费精品人妻一区二区| 国产亚洲精品av在线| 在线国产一区二区在线| 小蜜桃在线观看免费完整版高清| 国产蜜桃级精品一区二区三区| 国产一区在线观看成人免费| 国产成人系列免费观看| 午夜影院日韩av| 午夜福利在线在线| 精品人妻1区二区| 国产男靠女视频免费网站| 啦啦啦免费观看视频1| 国内揄拍国产精品人妻在线| 18禁国产床啪视频网站| 97超视频在线观看视频| 亚洲精品国产精品久久久不卡| 欧美日韩中文字幕国产精品一区二区三区| 一个人免费在线观看的高清视频| 极品教师在线免费播放| 欧美成人性av电影在线观看| a级毛片在线看网站| 桃红色精品国产亚洲av| 亚洲人与动物交配视频| 老司机午夜福利在线观看视频| 熟女少妇亚洲综合色aaa.| 国产又黄又爽又无遮挡在线| 男女那种视频在线观看| 国产精品野战在线观看| 国产精品99久久久久久久久| 婷婷亚洲欧美| 麻豆成人av在线观看| 国产精品综合久久久久久久免费| 又粗又爽又猛毛片免费看| 国产精品影院久久| 精品不卡国产一区二区三区| 麻豆久久精品国产亚洲av| 村上凉子中文字幕在线| 色吧在线观看| 久久久久久大精品| 叶爱在线成人免费视频播放| cao死你这个sao货| 色精品久久人妻99蜜桃| 亚洲色图 男人天堂 中文字幕| 国产淫片久久久久久久久 | 午夜日韩欧美国产| 一个人看视频在线观看www免费 | 国产午夜福利久久久久久| 久久精品人妻少妇| 一a级毛片在线观看| 午夜免费观看网址| 成人特级av手机在线观看| 亚洲av第一区精品v没综合| 午夜免费激情av| 18禁黄网站禁片午夜丰满| 亚洲人成伊人成综合网2020| 精品午夜福利视频在线观看一区| 天堂影院成人在线观看| 韩国av一区二区三区四区| 一本综合久久免费| 黄色日韩在线| 两个人的视频大全免费| 少妇人妻一区二区三区视频| 97超视频在线观看视频| 观看美女的网站| 国产成人影院久久av| 久久久久性生活片| 亚洲精品乱码久久久v下载方式 | 亚洲av中文字字幕乱码综合| 中文资源天堂在线| 在线观看免费视频日本深夜| 亚洲精品在线观看二区| 久久精品夜夜夜夜夜久久蜜豆| 久久中文看片网| 国产一区二区激情短视频| 69av精品久久久久久| 成人av在线播放网站| 欧美黄色淫秽网站| 久久精品国产综合久久久| 一级黄色大片毛片| 黄色日韩在线| 又粗又爽又猛毛片免费看| 99久久精品热视频| 国产三级黄色录像| 久久亚洲真实| 舔av片在线| 国产精品日韩av在线免费观看| 制服丝袜大香蕉在线| 淫秽高清视频在线观看| 色综合站精品国产| 19禁男女啪啪无遮挡网站| 成人特级av手机在线观看| 亚洲国产精品成人综合色| 久9热在线精品视频| 国产v大片淫在线免费观看| 久久国产精品人妻蜜桃| 亚洲午夜理论影院| h日本视频在线播放| 女同久久另类99精品国产91| 97碰自拍视频| avwww免费| 日韩三级视频一区二区三区| 欧美成人性av电影在线观看| 香蕉国产在线看| 夜夜夜夜夜久久久久| 两个人看的免费小视频| 免费在线观看视频国产中文字幕亚洲| 午夜两性在线视频| 女人高潮潮喷娇喘18禁视频| 精品国产美女av久久久久小说| 亚洲性夜色夜夜综合| 两性夫妻黄色片| 午夜福利成人在线免费观看| 一级毛片高清免费大全| 亚洲成人免费电影在线观看| 女人高潮潮喷娇喘18禁视频| 久久精品影院6| 母亲3免费完整高清在线观看| 麻豆成人午夜福利视频| 亚洲av电影不卡..在线观看| 啦啦啦观看免费观看视频高清| 成人国产综合亚洲| 一区二区三区高清视频在线| 国产不卡一卡二| 琪琪午夜伦伦电影理论片6080| 亚洲七黄色美女视频| 亚洲aⅴ乱码一区二区在线播放| 亚洲精品久久国产高清桃花| 国产视频内射| 制服人妻中文乱码| 国产精品99久久久久久久久| 国产99白浆流出| www日本黄色视频网| 亚洲中文av在线| 一边摸一边抽搐一进一小说| 成年免费大片在线观看| 精品久久久久久久久久免费视频| 日本熟妇午夜| 不卡一级毛片| 中文字幕人成人乱码亚洲影| 免费高清视频大片| 性色avwww在线观看| 精品久久蜜臀av无| 人妻丰满熟妇av一区二区三区| 国产乱人伦免费视频| 人人妻人人澡欧美一区二区| 天堂动漫精品| 日韩av在线大香蕉| 成人鲁丝片一二三区免费| 看免费av毛片| 九九在线视频观看精品| 成人三级黄色视频| 一进一出好大好爽视频| 一个人免费在线观看电影 | 国语自产精品视频在线第100页| 99国产极品粉嫩在线观看| 丰满人妻一区二区三区视频av | av欧美777| 亚洲av日韩精品久久久久久密| 一本久久中文字幕| 国产久久久一区二区三区| 国产伦一二天堂av在线观看| 国内精品美女久久久久久| 精品国产三级普通话版| or卡值多少钱| 久久久久性生活片| 麻豆一二三区av精品| 人妻夜夜爽99麻豆av| 久久中文看片网| 亚洲五月天丁香| 日韩欧美在线二视频| 不卡av一区二区三区| 久久精品人妻少妇| 国产午夜精品久久久久久| 一个人观看的视频www高清免费观看 | 窝窝影院91人妻| 12—13女人毛片做爰片一| 欧美黑人欧美精品刺激| 亚洲五月婷婷丁香| 亚洲国产精品久久男人天堂| 99国产精品一区二区三区| 午夜福利在线在线| 久久精品综合一区二区三区| 99精品久久久久人妻精品| 国产精品一区二区免费欧美| 成年版毛片免费区| 午夜a级毛片| 亚洲av第一区精品v没综合| 性欧美人与动物交配| 亚洲自偷自拍图片 自拍| 亚洲精品一区av在线观看| 叶爱在线成人免费视频播放| 女人被狂操c到高潮| 不卡av一区二区三区| 亚洲精品一区av在线观看| 成在线人永久免费视频| 精品一区二区三区四区五区乱码| 国产激情偷乱视频一区二区| 九九在线视频观看精品| 国产欧美日韩一区二区三| 日韩av在线大香蕉| 色av中文字幕| 岛国在线观看网站| 丁香欧美五月| 香蕉丝袜av| 婷婷丁香在线五月| 国产精品99久久久久久久久| 村上凉子中文字幕在线| 免费观看人在逋| 欧美日韩一级在线毛片| 欧美最黄视频在线播放免费| 亚洲成人免费电影在线观看| 1024香蕉在线观看| 久久久久九九精品影院| 亚洲欧洲精品一区二区精品久久久| 亚洲欧美精品综合一区二区三区| 久久这里只有精品中国| 一个人观看的视频www高清免费观看 | 国产欧美日韩一区二区精品| 亚洲在线观看片| av在线蜜桃| 99精品欧美一区二区三区四区| 中亚洲国语对白在线视频| www.精华液| 国产乱人伦免费视频| 国产高清激情床上av| 一边摸一边抽搐一进一小说| bbb黄色大片| 午夜成年电影在线免费观看| 日韩国内少妇激情av| 美女免费视频网站| 91av网站免费观看| 精品午夜福利视频在线观看一区| 老熟妇乱子伦视频在线观看| 男女下面进入的视频免费午夜| 狠狠狠狠99中文字幕| 婷婷丁香在线五月| 亚洲av五月六月丁香网| 午夜a级毛片| 亚洲精品久久国产高清桃花| 精品久久久久久久久久久久久| 一级黄色大片毛片| 黄片小视频在线播放| 久久午夜亚洲精品久久| 精品久久久久久久久久免费视频| 亚洲精品在线美女| 老汉色av国产亚洲站长工具| 精品一区二区三区视频在线 | 最新美女视频免费是黄的| 久久香蕉精品热| 中文字幕人妻丝袜一区二区| 两性夫妻黄色片| 啦啦啦韩国在线观看视频| 久久精品人妻少妇| 中文字幕人妻丝袜一区二区| 无人区码免费观看不卡| 啦啦啦韩国在线观看视频| 波多野结衣高清无吗| 久久精品综合一区二区三区| 女警被强在线播放| 国产探花在线观看一区二区| 人人妻,人人澡人人爽秒播| 哪里可以看免费的av片| 又大又爽又粗| 天堂影院成人在线观看| 国产精品99久久久久久久久| 日韩欧美 国产精品| 亚洲精品粉嫩美女一区| 色视频www国产| 激情在线观看视频在线高清| 久久99热这里只有精品18| 色播亚洲综合网| 亚洲人成网站高清观看| 国产爱豆传媒在线观看| 欧美性猛交黑人性爽| 99精品久久久久人妻精品| 一区二区三区国产精品乱码| 婷婷精品国产亚洲av在线| 成在线人永久免费视频| 老司机午夜福利在线观看视频| 网址你懂的国产日韩在线| 国产成年人精品一区二区| 国产精华一区二区三区| 亚洲avbb在线观看| 少妇的丰满在线观看| 99在线视频只有这里精品首页| 亚洲中文av在线| 一区二区三区激情视频| 熟妇人妻久久中文字幕3abv| 无限看片的www在线观看| 超碰成人久久| 亚洲欧美日韩无卡精品| 亚洲七黄色美女视频| 国产激情久久老熟女| 国产一区二区三区视频了| 床上黄色一级片| 亚洲精品456在线播放app | 一本综合久久免费| 色噜噜av男人的天堂激情| 欧美xxxx黑人xx丫x性爽| 日韩大尺度精品在线看网址| 18禁观看日本| 国产精品精品国产色婷婷| 欧美日韩亚洲国产一区二区在线观看| 女同久久另类99精品国产91| 国产亚洲欧美在线一区二区| 欧美3d第一页| 亚洲va日本ⅴa欧美va伊人久久| 日韩 欧美 亚洲 中文字幕| 久久久久国内视频| 国产精品野战在线观看| 午夜福利欧美成人| 欧美成狂野欧美在线观看| 亚洲国产欧美网| 国产真人三级小视频在线观看| 99riav亚洲国产免费| 啦啦啦观看免费观看视频高清| www.自偷自拍.com| 日韩av在线大香蕉| 可以在线观看毛片的网站| 男女做爰动态图高潮gif福利片| 毛片女人毛片| 亚洲国产欧美网| 亚洲美女视频黄频| 久久性视频一级片| 中文资源天堂在线| 1024香蕉在线观看| 国产日本99.免费观看| 国产精品一区二区三区四区免费观看 | 18禁黄网站禁片免费观看直播| 国产精品九九99| 亚洲人成伊人成综合网2020| netflix在线观看网站| 国产精品久久久久久久电影 | 长腿黑丝高跟| 亚洲成a人片在线一区二区| 亚洲专区国产一区二区| 日韩欧美三级三区| e午夜精品久久久久久久| 国产亚洲精品久久久久久毛片| 亚洲中文av在线| 精品99又大又爽又粗少妇毛片 | 夜夜看夜夜爽夜夜摸| 国产成人福利小说| 国产日本99.免费观看| 手机成人av网站| 成年女人永久免费观看视频| 色尼玛亚洲综合影院| 亚洲av成人不卡在线观看播放网| 亚洲精品中文字幕一二三四区| 久久热在线av| 男女午夜视频在线观看| 国产精品久久久久久久电影 | 国产精品国产高清国产av| 色吧在线观看| 99久久精品国产亚洲精品| 亚洲国产高清在线一区二区三| 日韩精品青青久久久久久| 男人舔女人下体高潮全视频| 男插女下体视频免费在线播放| 一级毛片高清免费大全| 久久精品国产亚洲av香蕉五月| 国产成人av教育| 中文亚洲av片在线观看爽| 久久久国产精品麻豆| 欧美国产日韩亚洲一区| 大型黄色视频在线免费观看| 亚洲av熟女| 成人一区二区视频在线观看| 国产真人三级小视频在线观看| 欧美色视频一区免费| 欧美乱色亚洲激情| 国产精品一及| 精品无人区乱码1区二区| 日本成人三级电影网站| 成在线人永久免费视频| 一卡2卡三卡四卡精品乱码亚洲| 国产午夜福利久久久久久| 91av网站免费观看| 亚洲av中文字字幕乱码综合| 国产欧美日韩一区二区三| 欧美色欧美亚洲另类二区| 亚洲av五月六月丁香网| 欧美性猛交黑人性爽| 中文字幕最新亚洲高清| 男人舔奶头视频| 麻豆av在线久日| 国产伦精品一区二区三区四那| 中文字幕人成人乱码亚洲影| 亚洲人成电影免费在线| 老熟妇乱子伦视频在线观看| 久久久久久久午夜电影| 国产人伦9x9x在线观看| 婷婷精品国产亚洲av在线| 在线观看午夜福利视频| 亚洲国产日韩欧美精品在线观看 | 国产91精品成人一区二区三区| aaaaa片日本免费| 动漫黄色视频在线观看| 91在线精品国自产拍蜜月 | 久久久久久久久免费视频了| 国产一区二区在线观看日韩 | 国产精品av久久久久免费| 国产在线精品亚洲第一网站| 日韩成人在线观看一区二区三区| 亚洲成av人片免费观看| 在线十欧美十亚洲十日本专区| 成年女人永久免费观看视频| 国产精品永久免费网站| 18禁黄网站禁片免费观看直播| 熟女人妻精品中文字幕| 熟女电影av网| 日本a在线网址| 国产激情偷乱视频一区二区| 久久精品国产清高在天天线| 国产日本99.免费观看| 动漫黄色视频在线观看| а√天堂www在线а√下载| 色综合婷婷激情| 欧美黄色片欧美黄色片| 日本三级黄在线观看| 日韩成人在线观看一区二区三区| 黄色片一级片一级黄色片| 欧美三级亚洲精品| 最近最新免费中文字幕在线| 熟妇人妻久久中文字幕3abv| 哪里可以看免费的av片| 欧美另类亚洲清纯唯美| 精品久久久久久,| 亚洲国产色片| 国语自产精品视频在线第100页| 久久中文字幕一级| 亚洲av中文字字幕乱码综合| 国产高清视频在线观看网站| 久久草成人影院| 亚洲成人久久性| 两个人视频免费观看高清| 亚洲中文日韩欧美视频| 亚洲熟妇熟女久久| 91老司机精品| 国产精品久久久久久精品电影| av片东京热男人的天堂| 精品电影一区二区在线| 后天国语完整版免费观看| 老熟妇乱子伦视频在线观看| 制服丝袜大香蕉在线| 黑人操中国人逼视频| 俄罗斯特黄特色一大片| 亚洲午夜理论影院| 欧美一区二区国产精品久久精品| 欧美大码av| 在线永久观看黄色视频| 国产久久久一区二区三区| 亚洲成人中文字幕在线播放| 国产精品亚洲av一区麻豆| 此物有八面人人有两片| 久久午夜亚洲精品久久| 一区二区三区激情视频| 日韩av在线大香蕉| 国内精品一区二区在线观看| 99国产综合亚洲精品| 看片在线看免费视频| 久久精品影院6| 国产成人av激情在线播放| 88av欧美| 久久午夜综合久久蜜桃| 午夜免费观看网址| 日韩欧美国产在线观看| 亚洲美女视频黄频| 欧美成人免费av一区二区三区| 在线视频色国产色| 在线免费观看不下载黄p国产 | 国产精品久久久久久亚洲av鲁大| 成年人黄色毛片网站| 国产99白浆流出| 禁无遮挡网站| 亚洲国产高清在线一区二区三| 免费看十八禁软件| 麻豆成人av在线观看| 母亲3免费完整高清在线观看| 老熟妇乱子伦视频在线观看| 欧美zozozo另类| 一个人看的www免费观看视频| 制服丝袜大香蕉在线| 国产精品99久久久久久久久| 亚洲无线在线观看| 丁香六月欧美| 亚洲熟妇中文字幕五十中出| 日本一本二区三区精品| 男女床上黄色一级片免费看| 九色国产91popny在线| 国产精品,欧美在线| 一本精品99久久精品77| 最新中文字幕久久久久 | 国产1区2区3区精品| 白带黄色成豆腐渣| 国产精品女同一区二区软件 | 欧美乱码精品一区二区三区| 国内毛片毛片毛片毛片毛片| 亚洲自偷自拍图片 自拍| 一夜夜www| 亚洲av五月六月丁香网| 亚洲国产欧美一区二区综合| 亚洲最大成人中文| 欧美激情在线99| 好看av亚洲va欧美ⅴa在| 极品教师在线免费播放| 欧美乱色亚洲激情| 两个人视频免费观看高清| 亚洲国产精品合色在线| 嫩草影院入口| av福利片在线观看| 一本久久中文字幕| 亚洲中文字幕日韩| 久久久色成人| 18禁观看日本| 女人被狂操c到高潮| 啦啦啦免费观看视频1| 婷婷丁香在线五月| 在线永久观看黄色视频| 国产 一区 欧美 日韩| 久久精品人妻少妇| 国产97色在线日韩免费| 中文字幕人成人乱码亚洲影| 国产精品永久免费网站|